|Valsartan||Angiotensin II receptor antagonist|
|Trade names||Co-vasotec, Diovan HCT, Co-Diovan, others|
|Defined daily dose||not established|
|AHFS/Drugs.com||FDA Professional Drug Information|
Valsartan/hydrochlorothiazide, sold under the trade name Co-Diovan among others, is an medication used to treat high blood pressure when valsartan is not sufficient. It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide, a diuretic. It is taken by mouth.
The combination was approved for medical use in the United States in 1998. It is available as a generic medication. A month supply in the United Kingdom costs the NHS about 1.85 as of 2019. In the United States the wholesale cost of this amount is about US$4.40. In 2017, it was the 133rd most commonly prescribed medication in the United States, with more than five million prescriptions.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 10 September 2020.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 179. ISBN 9780857113382.
- "Hydrochlorothiazide and valsartan Uses, Side Effects & Warnings". Drugs.com. Retrieved 10 March 2019.
- "Valsartan and Hydrochlorothiazide - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 10 March 2019.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- "Hydrochlorothiazide; Valsartan - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- "Hydrochlorothiazide mixture with valsartan". Drug Information Portal. U.S. National Library of Medicine.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|